Neogenomics (NEO) PT Lowered to $17 at BTIG
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
NeoGenomics Reports Fourth Quarter and Full Year 2024 Results
February 18, 2025 7:05 AM EST
Full Year Revenue Increased 12% to $661 million;
Ninth Consecutive Quarter of Double-Digit Revenue Growth
FORT MYERS, Fla.--(BUSINESS WIRE)-- NeoGenomics, Inc. (Nasdaq: NEO) (the Company), a leading oncology testing services company, today announced its fourth-quarter and full year results for the period ended December 31, 2024.
Fourth Quarter and Full Year 2024... More
